These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33495462)

  • 1. Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1.
    Zhang HT; Gui T; Liu RX; Tong KL; Wu CJ; Li Z; Huang X; Xu QT; Yang J; Tang W; Sang Y; Liu W; Liu N; Ross RD; He QY; Zha ZG
    Cell Death Dis; 2021 Jan; 12(1):121. PubMed ID: 33495462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.
    Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG
    J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence.
    Webber LP; Yujra VQ; Vargas PA; Martins MD; Squarize CH; Castilho RM
    Cancer Lett; 2019 Oct; 461():10-20. PubMed ID: 31265875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells.
    Wu Y; Zheng Q; Li Y; Wang G; Gao S; Zhang X; Yan X; Zhang X; Xie J; Wang Y; Sun X; Meng X; Yin B; Wang B
    J Exp Clin Cancer Res; 2019 Aug; 38(1):376. PubMed ID: 31455378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
    Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
    Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of BET bromodomain targets genetically diverse glioblastoma.
    Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J
    Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines.
    Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S
    Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
    Graham K; Lienau P; Bader B; Prechtl S; Naujoks J; Lesche R; Weiske J; Kuehnlenz J; Brzezinka K; Potze L; Zanconato F; Nicke B; Montebaur A; Bone W; Golfier S; Kaulfuss S; Kopitz C; Pilari S; Steuber H; Hayat S; Kamburov A; Steffen A; Schlicker A; Buchgraber P; Braeuer N; Font NA; Heinrich T; Kuhnke L; Nowak-Reppel K; Stresemann C; Steigemann P; Walter AO; Blotta S; Ocker M; Lakner A; von Nussbaum F; Mumberg D; Eis K; Piccolo S; Lange M
    Cell Chem Biol; 2024 Jul; 31(7):1247-1263.e16. PubMed ID: 38537632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
    Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
    Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP1 enhances NF-κB-dependent and independent effects on clock-mediated unfolded protein responses and autophagy in sarcoma.
    Rivera-Reyes A; Ye S; E Marino G; Egolf S; E Ciotti G; Chor S; Liu Y; Posimo JM; Park PMC; Pak K; Babichev Y; Sostre-Colón J; Tameire F; Leli NM; Koumenis C; C Brady D; Mancuso A; Weber K; Gladdy R; Qi J; Eisinger-Mathason TSK
    Cell Death Dis; 2018 Oct; 9(11):1108. PubMed ID: 30382078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.
    Rajendran P; Johnson G; Li L; Chen YS; Dashwood M; Nguyen N; Ulusan A; Ertem F; Zhang M; Li J; Sun D; Huang Y; Wang S; Leung HC; Lieberman D; Beaver L; Ho E; Bedford M; Chang K; Vilar E; Dashwood R
    Cancer Res; 2019 Mar; 79(5):918-927. PubMed ID: 30643017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.